Abstract
Estrogen has been implicated in promoting breast cancer in a majority of women. Endocrine therapy controlling estrogen production has been the guiding principle in treating breast cancer for more than a century. A greater understanding of this disease at a molecular level has led to the development of molecules that inhibit estrogen production by inhibiting the aromatase enzyme, that is the primary source of estrogen in postmenopausal women. This review examines the evolution of aromatase inhibitor (AI) based therapies over the past three decades. The third generation aromatase inhibitors (anastrozole, letrozole and exemestane), which have been found to be extremely specific and effective in an adjuvant/neoadjuvant/extended adjuvant setting are discussed from a biochemical and clinical perspective. A comprehensive discussion of the past, present, and future of aromatase inhibitors is conducted in this review.
Similar content being viewed by others
References
ACS. American Cancer Society Breast Cancer Facts and Figures 1997–2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp, Accessed October 17, 2007.
Boyd S. On oophorectomy in the treatment of cancer. Br Med J 1897;2:890–6.
Boyd S. Remarks on oophorectomy in treatment of cancer. Br Med J 1899;1:257–62.
Lemon HM. Abnormal estrogen metabolism and tissue estrogen receptor proteins in breast cancer. Cancer 1970;25:423–35.
Cutts JH. Estrogen-induced breast cancer in the rat. Proc Can Cancer Res Conf 1966;6:50–68.
Bouchardy C, Morabia A, Verkooijen HM, et al. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 2006;6:78.
Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491–500.
Wile AG, DiSaia PJ. Hormones and breast cancer. Am J Surg 1989;157:438–42.
ACS. Breast Cancer Facts and Figures 1997–2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp, Accessed October 17, 2007.
Worley RJ. Age, estrogen, and bone density. Clin Obstet Gynecol 1981;24:203–18.
Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181–210.
Bentrem DJ, Gaiha P, Jordan VC. Oestrogens, oestrogen receptors and breast cancer. EJC Suppl 2003;1:1–12.
Jordan VC. Targeting antihormone resistance in breast cancer: a simple solution. Ann Oncol 2003;14:969–70.
Liu J, Liu H, van Breemen RB, Thatcher GRJ, Bolton JL. Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol 2005;18:174–82.
Brueggemeier RW. Aromatase inhibitors—mechanisms of steroidal inhibitors. Breast Cancer Res Treat 1994;30:31–42.
Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26:331–45.
Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342–55.
Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a Food and Drug Administration-approved aromatase inhibitor. Cancer Res 2006;66:10281–6.
Brueggemeier RW. Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother 2006;7:1919–30.
Camacho AM, Kowarski A, Migeon CJ, Brough AJ. Congenital adrenal hyperplasia due to a deficiency of one of the enzymes involved in the biosynthesis of pregnenolone. J Clin Endocrinol Metab 1968;28:153–61.
Cocconi G. First generation aromatase inhibitors—aminoglutethimide and testololactone. Breast Cancer Res Treat 1994;30:57–80.
Dexter RN, Fishman LM, Ney RL, Liddle GW. An effect of adrenocorticotrophic hormone on adrenal cholesterol accumulation. Endocrinology 1967;81:1185–7.
Dexter RN, Fishman LM, Ney RL, Liddle GW. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action. J Clin Endocrinol Metab 1967;27:473–80.
Fishman LM, Liddle GW, Island DP, Fleischer N, Kuchel O. Effects of amino-glutethimide on adrenal function in man. J Clin Endocrinol Metab 1967;27:481–90.
Cash R, Brough AJ, Cohen MN, Satoh PS. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967;27:1239–48.
Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. Preliminary trial of aminoglutethimide in breast cancer. Cancer 1973;32:31–7.
Lipton A, Santen RJ. Proceedings: medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 1974;33:503–12.
Lipton A, Harvey HA, Santen RJ, et al. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 1982;50:2265–8.
Santen RJ, Worgul TJ, Samojlik E, et al. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Cancer Res 1982;42:3397s–401s.
Harvey HA, Santen RJ, Osterman J, et al. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 1979;43:2207–14.
Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, et al. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 1988;45:350–3.
Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 1981;283:1432–4.
Santen RJ, Worgul TJ, Lipton A, et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982;96:94–101.
Brufman G, Biran S. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 1990;29:717–20.
Buzdar AU, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer 1982;50:1708–12.
Kaye SB, Woods RL, Fox RM, Coates AS, Tattersall MH. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 1982;42:3445s–7s.
Kvinnsland S, Dahl O. Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach. Breast Cancer Res Treat 1983;3:73–6.
Murray RM, Pitt P. Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Res Treat 1981;1:91–5.
Nemoto T, Rosner D, Patel JK, Dao TL. Aminoglutethimide in patients with metastatic breast cancer. Cancer 1989;63:1673–5.
Schmid M, Jakesz R, Samonigg H, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003;21:984–90.
Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001;19:4209–15.
Segaloff A, Weeth JB, Cuningham M, Meyer KK. Hormonal therapy in cancer of the breast. 23. Effect of 7-alpha-methyl-19-nortestosterone acetate and testosterone propionate on clinical course and hormonal excretion. Cancer 1964;17:1248–53.
Barone RM, Shamonki IM, Siiteri PK, Judd HL. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone. J Clin Endocrinol Metab 1979;49:672–6.
Brodie AM, Garrett WM, Hendrickson JR, et al. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 1981;38:693–702.
Coombes RC, Hughes SW, Dowsett M. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur J Cancer 1992;28A:1941–5.
Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992;43:155–9.
Lonning PE, Dowsett M, Jones A, et al. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res Treat 1992;23:57–62.
Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med 2005;56:103–16.
Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996;7:471–9.
Raats JI, Falkson G, Falkson HC. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 1992;10:111–6.
Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer 1996;77:2503–13.
Howell A, Howell SJ, Clarke R, Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 2001;79:227–37.
Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132–8.
Demers LM. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994;30:95–102.
di Salle E, Ornati G, Giudici D, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992;43:137–43.
Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103–11.
Plourde PV, Dyroff M, Dowsett M, et al. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;53:175–9.
Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933–9.
Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101–8.
Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000–11.
Dowsett M, Lonning PE. Anastrozole—a new generation in aromatase inhibition: clinical pharmacology. Oncology 1997;54 Suppl 2:11–4.
Dukes M, Edwards PN, Large M, Smith IK, Boyle T. The preclinical pharmacology of “Arimidex” (anastrozole; ZD1033)—a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996;58:439–45.
Bisagni G, Cocconi G, Scaglione F, et al. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99–102.
Dowsett M, Jones A, Johnston SR, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511–5.
Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–9.
Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486–92.
Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006;20 Suppl 1:S5–13.
Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99:295–300.
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.
Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2.
Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–43.
Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273–84.
Locker GY, Mansel R, Cella D, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007; doi:10.1007/s10549-006-9483-6.
Buzdar A, Chlebowski R, Cuzick J, et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006;22:1575–85.
Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–62.
Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991–6.
Jonat W, Hilpert F, Maass N. The use of aromatase inhibitors in adjuvant therapy for early breast cancer. Cancer Chemother Pharmacol 2005;56 Suppl 1:32–8.
Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–16.
Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 2006;106:2095–103.
Bhatnagar AS. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. Breast 2006;15 Suppl 1:S3–13.
Ansari TN, Mahmood A, Hussain I, Samad A. Efficacy of letrozole for advanced breast cancer in postmenopausal patients. J Coll Physicians Surg Pak 2005;15:204–6.
Scott LJ, Keam SJ. Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs 2006;66:353–62.
Forbes JF. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33:S2–7.
Monnier A. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98. Breast 2006;15 Suppl 1 S21–9.
Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931–40.
Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707–15.
Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–35.
Tominaga T, Adachi I, Sasaki Y, et al. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol 2003;14:62–70.
Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751–7.
Coombes RC, Bliss JM, Hall E. Safety of exemestane in the Intergroup Exemestane Study. J Clin Oncol 2005;23:3171–2.
Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910–7.
Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119–27.
Mamounas EP. Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology (Williston Park) 2001;15:35–9.
Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003;26:S27–33.
Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis 2005;24:107–17.
Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 2006;33:672–80.
NCI. (http://www.clinicaltrials.gov/show/NCT00248170). Clinical trials NCT00248170. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/ct/show/NCT00066573). Clinical trials NCT00066573. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00263913). Clinical trials NCT00263913. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/ct/show/NCT00265759). Clinical trials NCT00265759. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00228956). Clinical trials NCT00228956. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00126360). Clinical trials NCT00126360. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00171847). Clinical trials NCT00171847. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/ct/show/NCT00073528). Clinical trials NCT00073528. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00375752). Clinical trials NCT00375752. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00111241). Clinical trials NCT00111241. National Cancer Institute. Accessed October 17, 2007.
NCI. (http://www.clinicaltrials.gov/show/NCT00122356). Clinical trials NCT00122356. National Cancer Institute. Accessed October 17, 2007.
Grana G. Adjuvant aromatase inhibitor therapy for early breast cancer: a review of the most recent data. J Surg Oncol 2006;93:585–92.
Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41:1678–89.
Viale PH. Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment. Oncol Nurs Forum 2005;32:343–53.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dutta, U., Pant, K. Aromatase inhibitors: past, present and future in breast cancer therapy. Med Oncol 25, 113–124 (2008). https://doi.org/10.1007/s12032-007-9019-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-007-9019-x